Paralel Advisors LLC Acquires Shares of 185,831 Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Paralel Advisors LLC acquired 185,831 Amneal Pharmaceuticals shares worth approximately $3.2 million, while institutional investors collectively own 31.82% of the company.
• Analysts remain bullish on AMRX, with a consensus “Buy” rating and a $19.00 price target. UBS and Barclays recently raised their price targets, while several ratings services upgraded the stock.
• Amneal reported quarterly EPS of $0.30, beating estimates of $0.24, on revenue of $796.2 million. However, insiders sold 413,016 shares worth about $7.2 million over the past 90 days.

Paralel Advisors LLC bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 185,831 shares of the company's stock, valued at approximately $3,217,000. Paralel Advisors LLC owned 0.06% of Amneal Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Westshore Wealth LLC bought a new position in shares of Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley raised its holdings in shares of Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company's stock worth $60,708,000 after buying an additional 1,315,018 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company's stock worth $32,405,000 after acquiring an additional 1,069,400 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter worth approximately $17,573,000. Finally, Penn Capital Management Company LLC purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at $12,655,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 146,403 shares of the firm's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total transaction of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company's stock, valued at $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 413,016 shares of company stock valued at $7,216,567. 17.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have commented on AMRX. UBS Group upped their price objective on Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Barclays boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a research note on Wednesday, May 20th. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 26th. Zacks Research raised shares of Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $19.00.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $17.44 on Monday. The firm has a 50-day simple moving average of $17.76 and a 200-day simple moving average of $14.96. Amneal Pharmaceuticals, Inc. has a one year low of $9.44 and a one year high of $19.26. The firm has a market cap of $5.57 billion, a P/E ratio of 35.59 and a beta of 1.24. The company has a debt-to-equity ratio of 77.65, a quick ratio of 1.44 and a current ratio of 2.20.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.06. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.94 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source